公开(公告)号：US20060106220A1

公开(公告)日：2006-05-18

申请号：US11300976

申请日：2005-12-14

申请人： Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

发明人： Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

IPC分类号： A61K31/4745 ,  C07D471/04 ,  C07D405/02 ,  C07D409/02 ,  C07D401/02 ,  A61K31/4709

CPC分类号： C07D311/26 ,  A23L33/10 ,  A23L33/11 ,  A23V2002/00 ,  C07D311/36 ,  C07D311/38 ,  C07D311/58 ,  C07D471/06 ,  A23V2250/2116 ,  A23V2200/30

摘要： Isoflavone compounds and analogues thereof, compositions containing same and therapeutic methods of treatment involving same are described.

摘要翻译： 描述异黄酮化合物及其类似物，含有其的组合物和涉及其的治疗方法。

公开(公告)号：US20060100238A1

公开(公告)日：2006-05-11

申请号：US10532074

申请日：2003-11-02

申请人： Graham Kelly ,  Andrew Heaton ,  John Bremner

发明人： Graham Kelly ,  Andrew Heaton ,  John Bremner

IPC分类号： A61K31/4704 ,  A61K31/4706 ,  A61K31/382 ,  A61K31/353

CPC分类号： A61K31/352 ,  C07D311/68

摘要： Aminated isoflavonoid synthesized by aminating the 4-keto group of isoflavanone and isoflavanone ring systems, pharmaceutical compositions containing same and uses thereof as therapeutic agents.

摘要翻译： 通过胺化异黄酮和异黄烷酮环系的4-酮基合成的氨基异黄酮，含有其的药物组合物和其用作治疗剂。

公开(公告)号：US20080014249A1

公开(公告)日：2008-01-17

申请号：US11901724

申请日：2007-09-17

申请人： Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

发明人： Andrew Heaton ,  Naresh Kumar ,  Graham Kelly ,  Alan Husband

IPC分类号： A61K47/00 ,  A61K31/35 ,  A61P29/00 ,  A61K31/355

CPC分类号： C07D311/26 ,  A23L33/10 ,  A23L33/11 ,  A23V2002/00 ,  C07D311/36 ,  C07D311/38 ,  C07D311/58 ,  C07D471/06 ,  A23V2250/2116 ,  A23V2200/30

摘要： Isoflavone compounds are described and recommended as therapeutic agents. Exemplified and preferred compounds are (a). Indications show compounds have good competitive binding to estrogen receptors. This is exemplified.

摘要翻译： 描述和推荐异黄酮化合物作为治疗剂。 示例性和优选的化合物是（a）。 适应症显示化合物与雌激素受体具有良好的竞争性结合。 这是例证。

公开(公告)号：US20070244075A1

公开(公告)日：2007-10-18

申请号：US10579789

申请日：2004-11-18

申请人： Andrew Heaton ,  Graham Kelly

发明人： Andrew Heaton ,  Graham Kelly

IPC分类号： A61K31/662 ,  A61P15/00 ,  C07F9/09

CPC分类号： C07F9/65522 ,  A23L2/52 ,  A23L33/10 ,  A23V2002/00 ,  A23V2200/308 ,  A23V2200/322 ,  A23V2200/318 ,  A23V2200/30 ,  A23V2250/2116

摘要： Phosphate esters of isoflavonoid compounds are prepared for use as prodrugs, medicaments and in formulations, drinks and foodstuffs.

摘要翻译： 制备异黄酮化合物的磷酸酯用作前药，药物和制剂，饮料和食品。

公开(公告)号：US20050049424A1

公开(公告)日：2005-03-03

申请号：US10493390

申请日：2002-10-25

申请人： Graham Kelly ,  Andrew Heaton

发明人： Graham Kelly ,  Andrew Heaton

IPC分类号： A61K31/12 ,  A61K31/352 ,  A61K31/353 ,  A61P1/00 ,  A61P1/16 ,  A61P3/10 ,  A61P7/00 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P13/08 ,  A61P15/00 ,  A61P17/00 ,  A61P21/04 ,  A61P25/00 ,  A61P25/16 ,  A61P25/18 ,  A61P25/28 ,  A61P27/02 ,  A61P27/12 ,  A61P35/00 ,  A61P37/00 ,  A61P43/00 ,  C07C45/46 ,  C07C49/83 ,  C07C49/835 ,  C07D311/36 ,  C07D471/06 ,  C07D307/77 ,  C07D323/02

CPC分类号： C07D311/36 ,  A61K31/12 ,  A61K31/352 ,  A61K31/353 ,  C07C45/46 ,  C07C49/83 ,  C07C49/835 ,  C07D471/06

摘要： Isoflavone compounds of the formula (I) or (II) Where R can be R7? or OR7? or O and the formula (III) is either a single or double bond extends to Y then Y is an optionally substituted benzyl. W, R1?, Zo? R2? and R7? are as defined in the specification. The compounds are useful for the treatment of certain diseases and disorders, including cancer and inflammation.

摘要翻译： 式（I）或（II）的异黄酮化合物其中R可以是R 7？ 或OR 7？ 或O，式（III）是单键或双键延伸至Y，则Y为任选取代的苄基。 W，R 1 ?, Z o？ R 2？ 和R 7？ 如说明书中所定义。 该化合物可用于治疗某些疾病和病症，包括癌症和炎症。

公开(公告)号：US20070142320A1

公开(公告)日：2007-06-21

申请号：US11499904

申请日：2006-08-04

申请人： Graham Kelly

发明人： Graham Kelly

IPC分类号： A61K31/716 ,  C08B37/00

CPC分类号： A61Q17/04 ,  A61K8/73 ,  A61K31/716 ,  A61L26/0023 ,  A61Q19/004 ,  A61Q19/08 ,  C08B37/0024 ,  C12P19/04 ,  Y10S514/925 ,  Y10S514/928 ,  C08L5/00

摘要： A process for the production of β-(1,3)(1,6) glucan from a glucan containing cellular source is described, together with compositions and uses/methods of treatment involving glucan. The process of the invention comprises the steps of: (a) extracting glucan containing cells with alkali and heat, in order to remove alkali soluble components; (b) acid extracting the cells of step (a) with an acid and heat to form a suspension; (c) extracting the suspension obtained of step (b) or recovered hydrolyzed cells with an organic solvent which is non-miscible with water and which has a density greater than that of water separating the resultant aqueous phase, solvent containing phase and interface so that substantially only the aqueous phase comprising β-(1,3)(1,6) glucan particulate material remains; wherein the extraction with said organic solvent provides separation of glucan subgroups comprising branched β-(1,3)(1,6)-glucan, and essentially unbranched β-(1,3) glucan which is associated with residual non-glucan contaminents; and (d) drying the glucan material from step (c) to give microparticulate glucan.

摘要翻译： 描述了从含葡聚糖的细胞源生产β-（1,3）（1,6）葡聚糖的方法，以及涉及葡聚糖的组合物和用途/治疗方法。 本发明的方法包括以下步骤：（a）用碱和热提取含葡聚糖的细胞，以除去碱溶性组分; （b）用酸和热将酸步骤（a）的细胞萃取以形成悬浮液; （c）用与水不溶的有机溶剂提取步骤（b）获得的悬浮液或回收的水解细胞，其密度大于分离所得水相，含溶剂相和界面的水的密度，使得 基本上只剩下包含β-（1,3）（1,6）葡聚糖颗粒材料的水相; 其中用所述有机溶剂萃取提供葡聚糖亚组的分离，所述葡聚糖亚组包含与残留的非葡聚糖污染物相关的支链β-（1,3）（1,6） - 葡聚糖和基本上未分支的β-（1,3）葡聚糖; 和（d）干燥步骤（c）的葡聚糖材料，得到微粒葡聚糖。

公开(公告)号：USD345196S

公开(公告)日：1994-03-15

申请号：US938479

申请日：1992-09-01

申请人： Graham Kelly

设计人： Graham Kelly

公开(公告)号：US20080215072A1

公开(公告)日：2008-09-04

申请号：US12017191

申请日：2008-01-21

申请人： Graham Kelly

发明人： Graham Kelly

IPC分类号： A61B17/12

CPC分类号： A61B17/12022 ,  A61B17/06166 ,  A61B17/12009 ,  A61B17/12109 ,  A61B17/12159 ,  A61B2017/06176 ,  A61F2/2475

摘要： A method and apparatus for eliminating or improving blood flow within incompetent veins to correct venous insufficiency using a barbed bidirectional suture with predetermined breaking point. Said suture may also be utilized for other tissue applications. A two-way barb suture is placed in an insertion device comprised of a tubular body with or without a pointed distal tip. The inserting device and one-way or two-way suture are placed in a position to effectively close off the vein or leave a device within the vein. The insertion device is then withdrawn leaving the suture in place. This barbed suture with predetermined breaking point is used by the method of the present invention to prevent reflux, and as a method to join body tissue, attach dissimilar body tissues, attach devices to body tissues, and alter the position of body tissues by remote percutaneous access with the assistance of ultrasound or fluoroscopy and with the assistance of endoscopic devices.

摘要翻译： 一种用于消除或改善无能力静脉内的血流的方法和装置，以使用具有预定断裂点的带倒钩的双向缝线来校正静脉功能不全。 所述缝合线也可用于其它组织应用。 将双向倒钩缝合线放置在包括具有或不具有尖锐远端的管状体的插入装置中。 插入装置和单向或双向缝合线被放置在有效地关闭静脉或将静脉内的装置留下的位置。 然后将插入装置取出离开缝合线就位。 通过本发明的方法使用具有预定断裂点的带刺缝合线来防止回流，并且作为连接身体组织的方法，将不同的身体组织附着，将装置附着到身体组织，并通过远程经皮改变身体组织的位置 在超声波或荧光透视辅助下，并借助内窥镜装置进行访问。

公开(公告)号：US20060153781A1

公开(公告)日：2006-07-13

申请号：US10526830

申请日：2003-09-05

申请人： Graham Kelly ,  Alan Husband ,  Cath Walker

发明人： Graham Kelly ,  Alan Husband ,  Cath Walker

IPC分类号： A61K8/49

CPC分类号： A61K8/498 ,  A61K31/12 ,  A61K31/35 ,  A61K31/40 ,  A61K31/475 ,  A61Q17/04

摘要： Methods for protecting skin from UV-induced DNA mutagenic damage comprising administration of one or more of equol, dehydroequol, isoflav-3-ene and isoflavan compounds in admixture with a dermally acceptable carrier are described. Also described are methods for preventing skin cancer formation.

摘要翻译： 描述了保护皮肤免受紫外线诱导的DNA诱变损伤的方法，其包括与皮肤可接受的载体混合施用一种或多种雌马酚，脱氢异丙醇，异黄酮-3-烯和异黄酮化合物。 还描述了防止皮肤癌形成的方法。

公开(公告)号：US20050131047A1

公开(公告)日：2005-06-16

申请号：US11024512

申请日：2004-12-28

申请人： Graham Kelly ,  George Joannou

发明人： Graham Kelly ,  George Joannou

IPC分类号： A23L2/52 ,  A23L1/30 ,  A61K8/49 ,  A61K31/12 ,  A61K31/122 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/382 ,  A61K31/40 ,  A61K31/404 ,  A61K31/47 ,  A61K31/4745 ,  A61P1/04 ,  A61P5/30 ,  A61P9/10 ,  A61P9/12 ,  A61P13/08 ,  A61P17/02 ,  A61P17/12 ,  A61P17/14 ,  A61P19/02 ,  A61P19/10 ,  A61P25/00 ,  A61P27/12 ,  A61P29/00 ,  A61P35/00 ,  A61P39/06 ,  A61Q7/00 ,  A61Q19/00 ,  C07C45/46 ,  C07C45/67 ,  C09K15/08 ,  C09K15/30 ,  C12P7/26 ,  C12P17/04 ,  C12P17/10 ,  A61K31/4172 ,  A61K31/05 ,  A61K31/24 ,  A61K31/401 ,  A61K31/405

CPC分类号： A61K8/498 ,  A61K8/35 ,  A61K8/492 ,  A61K31/12 ,  A61K31/352 ,  A61K31/353 ,  A61K31/355 ,  A61K31/40 ,  A61K31/404 ,  A61K31/405 ,  A61K31/47 ,  A61K31/4745 ,  A61K2800/522 ,  A61Q7/00 ,  A61Q19/00 ,  A61Q19/08 ,  C07C45/46 ,  C07C45/673 ,  C12P7/26 ,  C12P17/04 ,  C12P17/10 ,  A61K2300/00 ,  C07C49/83 ,  C07C49/84

摘要： Therapeutic methods of treatment, compositions and foodstuffs are described which contain isoflavone compounds described by general formula (I), in which Z is H, R1 is H, or RACO where RA is C1-10alkyl or an amino acid, R2 is H, OH, or ORB where RB is an amino acid, or CORA where RA is as previously defined, W is H, A is H or OH, and B is selected from (a), (b), (c), or W is H, and A and B taken together form a six-membered ring selected from (d), or W, A and B taken with the groups with which they are associated comprise (e), or W and A taken together with the groups with which they are associated comprise (f) and B is (g) wherein R3 is H, CORA where RA is as previously defined, CO2RC where RC is C1-10alkyl, or CORB where RB is as previously defined, R4 is H, CORD where RD is H, OH, C1-10alkyl or an amino acid, CO2RC where RC is as previously defined, CORE where RE is H. C1-10alkyl or an amino acid, COOH, CORC where RC is as previously defined, or CONHRE where RE is as previously defined, R5 is H, CORC where RC is as previously defined, or CORCORE where RC and RE are as previously defined, and where the two R5 groups are attached to the same group they are the same or different, R6 is H or hydroxy C1-10alkyl, X is preferably O, but may be N or S, and Y is (h) where R7 is H, or C1-10alkyl.